| Clinical use of dendritic cells for cancer therapy S Anguille, EL Smits, E Lion, VF van Tendeloo, ZN Berneman The lancet oncology 15 (7), e257-e267, 2014 | 761 | 2014 |
| Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia S Anguille, AL Van de Velde, EL Smits, VF Van Tendeloo, G Juliusson, ... Blood, The Journal of the American Society of Hematology 130 (15), 1713-1721, 2017 | 206 | 2017 |
| Poly (I: C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs R Ammi, J De Waele, Y Willemen, I Van Brussel, DM Schrijvers, E Lion, ... Pharmacology & therapeutics 146, 120-131, 2015 | 198 | 2015 |
| Dendritic cells as pharmacological tools for cancer immunotherapy S Anguille, EL Smits, C Bryant, HH Van Acker, H Goossens, E Lion, ... Pharmacological reviews 67 (4), 731-753, 2015 | 177 | 2015 |
| Natural killer cell immune escape in acute myeloid leukemia E Lion, Y Willemen, ZN Berneman, VFI Van Tendeloo, ELJ Smits Leukemia 26 (9), 2019-2026, 2012 | 167 | 2012 |
| Interferon-α in acute myeloid leukemia: an old drug revisited S Anguille, E Lion, Y Willemen, VFI Van Tendeloo, ZN Berneman, E Smits Leukemia 25 (5), 739-748, 2011 | 124 | 2011 |
| Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma G Roex, M Timmers, K Wouters, D Campillo-Davo, D Flumens, ... Journal of hematology & oncology 13, 1-14, 2020 | 122 | 2020 |
| Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells HH Van Acker, S Anguille, Y Willemen, JM Van den Bergh, ZN Berneman, ... Journal of hematology & oncology 9, 1-13, 2016 | 115 | 2016 |
| NK cells: key to success of DC-based cancer vaccines? E Lion, ELJM Smits, ZN Berneman, VFI Van Tendeloo The oncologist 17 (10), 1256-1270, 2012 | 110 | 2012 |
| Cold atmospheric plasma-treated PBS eliminates immunosuppressive pancreatic stellate cells and induces immunogenic cell death of pancreatic cancer cells J Van Loenhout, T Flieswasser, L Freire Boullosa, J De Waele, ... Cancers 11 (10), 1597, 2019 | 96 | 2019 |
| Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer M Versteven, JMJ Van den Bergh, E Marcq, ELJ Smits, VFI Van Tendeloo, ... Frontiers in immunology 9, 394, 2018 | 89 | 2018 |
| The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells ELJM Smits, N Cools, E Lion, K Van Camp, P Ponsaerts, ZN Berneman, ... Cancer Immunology, Immunotherapy 59, 35-46, 2010 | 76 | 2010 |
| Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy HH Van Acker, S Anguille, VF Van Tendeloo, E Lion Oncoimmunology 4 (8), e1021538, 2015 | 71 | 2015 |
| Interleukin-15 dendritic cells harness NK cell cytotoxic effector function in a contact-and IL-15-dependent manner S Anguille, HH Van Acker, J Van den Bergh, Y Willemen, H Goossens, ... PloS one 10 (5), e0123340, 2015 | 69 | 2015 |
| Dendritic cell-based immunotherapy of acute myeloid leukemia HH Van Acker, M Versteven, FS Lichtenegger, G Roex, D Campillo-Davo, ... Journal of clinical medicine 8 (5), 579, 2019 | 67 | 2019 |
| Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential S Anguille, E Lion, J Tel, IJM de Vries, K Coudere, PD Fromm, ... PloS one 7 (12), e51851, 2012 | 67 | 2012 |
| Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells JRM Van Audenaerde, J De Waele, E Marcq, J Van Loenhout, E Lion, ... Oncotarget 8 (34), 56968, 2017 | 65 | 2017 |
| The quest for the best: how TCR affinity, avidity, and functional avidity affect TCR-engineered T-cell antitumor responses D Campillo-Davo, D Flumens, E Lion Cells 9 (7), 1720, 2020 | 64 | 2020 |
| Dendritic cell vaccination in acute myeloid leukemia S Anguille, Y Willemen, E Lion, EL Smits, ZN Berneman Cytotherapy 14 (6), 647-656, 2012 | 62 | 2012 |
| Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients E Marcq, J De Waele, J Van Audenaerde, E Lion, E Santermans, N Hens, ... Oncotarget 8 (52), 89722, 2017 | 61 | 2017 |
